Decitabine is also known as 5 - nitrogen hetero - 2 '- DNA cytosine nucleoside, 5 - n - 2' - deoxy cytidine acid, is a kind of natural 2 '- deoxy cytidine acid adenosine analogues, by inhibiting the DNA methyltransferase, reduce DNA methylation, thus inhibiting tumor cell proliferation, and prevent the occurrence of drug resistance, for the strongest known DNA methylation specific inhibitor, belongs to the S phase of cell cycle specific drugs, is suitable for the treatment of myelodysplastic syndrome (MDS).

Market Analysis and Insights: Global Decitabine Market
In 2020, the global Decitabine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Decitabine Scope and Market Size
The global Decitabine market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Decitabine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
10 Mg Dosage Forms
15 Mg Dosage Forms
25 Mg Dosage Forms

Segment by Application
Primary MDS
Secondary MDS

By Company
Johnson & Johnson
Eli Lilly and Company
Pharmachemie B.V.
Otsuka Pharmaceutical
Sandoz
Dr Reddy's Laboratories
Accord Healthcare
Sun Pharmaceutical
Cipla
Lupin
Shandong Xinshidai Pharmaceutical
Hangzhou Zhongmei Huadong Pharmaceutical
ZHENGDA Tianqing Pharmaceutical Group
Jiangsu Aosaikang Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Lianyungang Jierui Pharmaceutical
Qilu Pharmaceutical Hainan
Lianyungang Runzhong Pharmaceutical

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE